Key points are not available for this paper at this time.
INTRODUCTION: Antibiotic resistance (ABR) may increase hospital costs, utility loss and mortality risk per patient. Understanding these losses at national, regional and global scales is necessary for efficiently tackling ABR. Our aim is to estimate the global economic burden of antibiotic-resistant infections and the potential for bacterial vaccines to mitigate this burden. METHODS: We take healthcare system and labour productivity perspectives. Hospital cost-per-case and length-of-stay estimates were calculated through meta-analyses and reviewing published systematic reviews. Unit labour productivity losses were estimated through a human capital approach. Modelled estimates were used where secondary data were missing. Death and incidence data were combined with unit cost data to estimate the economic burden associated with ABR in 2019, and the potential costs averted (in 2019 US) based on uptake scenarios of vaccines that currently exist or are likely to be developed. RESULTS: Multidrug-resistant tuberculosis had the highest mean hospital cost attributable to ABR per patient, the range was US3000 in lower-income settings to US41 000 in high-income settings, with carbapenem-resistant infections associated with a high cost-per-case of US3000-US7000 depending on syndrome. ABR was associated with a median value of US693 billion (IQR: US627 bn-US768 bn) in hospital costs globally, with US207 bn (IQR: US186 bn-US229 bn) potentially avertable by vaccines. Productivity losses were quantified at almost US194 billion, with US76 bn avertable by vaccines. CONCLUSIONS: would avert a substantial portion of the economic burden associated with ABR. More robust evidence, particularly in low-income countries, on the hospital costs, associated with and attributable to ABR, is needed.
Naylor et al. (Sun,) studied this question.